자가 줄기세포 및 비줄기세포 기반 치료 시장 보고서 : 유형별, 용도별, 최종 사용자별, 지역별(2025-2033년)

The global autologous stem cell and non-stem cell based therapies market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.8 Billion by 2033, exhibiting a growth rate (CAGR) of 11.5% during 2025-2033. The increasing prevalence of life-threatening diseases, the expanding geriatric population, and ongoing advancements in stem cell technologies represent some of the key factors driving the market.

Autologous stem cell therapy is a medical procedure in which a patient's stem cells are used to repair damaged tissues and organs or treat various diseases. The procedure involves harvesting stem cells from a patient's body, usually from bone marrow or adipose tissue, and then processing and injecting them back into the body. Non-stem cell-based therapies, on the other hand, involve using cells that are not stem cells, such as immune cells, fibroblasts, and muscle cells, to repair or regenerate damaged tissues or organs. Autologous stem cell therapy is used to treat cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders, while non-stem cell-based therapies are employed in treating chronic wounds, heart disease, and Parkinson's disease.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends:

The growth of the global autologous stem cell and non-stem cell based therapies market is primarily driven by the increasing prevalence of cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases due to smoking, poor diet, and sedentary lifestyles of consumers. Besides this, the rising geriatric population and the growing demand for autologous stem and non-stem cell based therapies are creating a positive outlook for the market. Moreover, the ongoing development of innovative autologous stem cell therapies for regenerative medicine and the widespread demand for personalized therapies are presenting remunerative growth opportunities for the market. In addition to this, the surging popularity of minimally invasive treatments, the expanding acceptance of stem cell therapies, and the implementation of favorable government initiatives, such as financial and regulatory support for stem cell research, are aiding in market expansion. Furthermore, continuous advancements in stem cell technologies have enabled researchers to better control the differentiation of stem cells and develop improved and effective treatments, which, in turn, is acting as a significant growth-inducing factor. Besides this, the bolstering growth of the healthcare sector, extensive research and development (R&D) activities, the escalating health consciousness among consumers, and favorable reimbursement policies are contributing to the market growth.

Key Market Segmentation:

Type Insights:

• Autologous Stem Cells
• Autologous Non-Stem Cells

Application Insights:

• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disease
• Orthopedic Diseases
• Others

End User Insights:

• Hospitals
• Ambulatory Surgical Centers
• Research Facilities

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for autologous stem cell and non-stem cell based therapies. Some of the factors driving the North America autologous stem cell and non-stem cell based therapies market included the expanding prevalence of chronic diseases, the rising demand for personalized medicines, and continuous advancements in stem cell technologies.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global autologous stem cell and non-stem cell based therapies market. Detailed profiles of all major companies have also been provided. Some of the companies covered include BrainStorm Cell Limited, Cytori Therapeutics Inc., Holostem Terapie Avanzate S.r.l., Lisata Therapeutics, U.S. Stem Cell Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global autologous stem cell and non-stem cell based therapies market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global autologous stem cell and non-stem cell based therapies market?
• What is the impact of each driver, restraint, and opportunity on the global autologous stem cell and non-stem cell based therapies market?
• What are the key regional markets?
• Which countries represent the most attractive autologous stem cell and non-stem cell based therapies market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the autologous stem cell and non-stem cell based therapies market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the autologous stem cell and non-stem cell based therapies market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the autologous stem cell and non-stem cell based therapies market?
• What is the competitive structure of the global autologous stem cell and non-stem cell based therapies market?
• Who are the key players/companies in the global autologous stem cell and non-stem cell based therapies market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Autologous Stem Cells
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Autologous Non-Stem Cells
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Neurodegenerative Disorders
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cardiovascular Disease
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Orthopedic Diseases
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Surgical Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Research Facilities
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 BrainStorm Cell Limited
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Cytori Therapeutics Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Holostem Terapie Avanzate S.r.l.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Lisata Therapeutics
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 U.S. Stem Cell Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.